Safety and Preliminary Efficacy of the Combination of Niclosamide and Camostat

Phase 2TerminatedNCT04750759

Charité Research Organisation GmbH4 enrolled

Overview

Niclosamide (2000 mg QD) and Camostate (600 mg QID) are expected to be safe and well-tolerated as a combination therapy and to show clinically beneficial for COVID-19 patients.

Niclosamide is an approved drug for the treatment of intestinal worm infections that can potentially induce the process of autophagy and thus significantly limit viral replication in cells. Camostat is approved in Japan for the treatment of chronic pancreatitis and reflux esophagitis. It has been shown to effectively block viral replication in a SARS-CoV-2 animal model. Since the mechanisms of actions are different, it was hypothesized that a combination of both substances might have an additive or even synergistic effect in the treatment of patients with COVID-19. This study is designed to investigate the safety, tolerability and preliminary efficacy of the treatment combination niclosamide and camostat in mild and moderately affected COVID-19 patients.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Covid19

Interventions

Niclosamide + CamostatDRUG

Niclosamide will be applied in combination with camostat.

PlaceboOTHER

Placebo to interventional drug

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male and female patients in the age of 18 to 70 years * Having a recent positive direct test for Sars-CoV-2 * Having mild or moderate COVID-19 symptoms with no indication for hospitalization due to SARS-CoV-2 infection (WHO Ordinal Scale 1-2) Exclusion Criteria: * Severe respiratory symptoms related to COVID-19 requiring oxygen or intensive care (high flow oxygen or mechanical ventilation or ECMO) * Patients with preexisting pulmonary diseases requiring oxygen supply * Patients with history of hypersensitivity to Camostat or Niclosamide or to any ingredients to any of the two drugs * Patients with heart failure (NYHA III or NYHA IV) * Patients with proven malignant tumor * Patients diagnosed with influenza infection * Pregnancy or breastfeeding * Immunocompromised patients * Creatinine clearance \< 60 mL/min * aspartate aminotransferase (AST) / alanine aminotransferase (ALT) \> 2 times upper limit of normal (ULN)

Locations (1)

Charité Research Organisation GmbH

Berlin, Germany

Outcomes

Primary Outcomes

Treatment emergent number of Adverse Events

All pathological and clinically significant findings in physical examinations, vital signs, 12-lead ECGs, oxygen saturation and safety lab including coagulation will be documented as adverse events. Adverse events will be reported on the basis of CTCAE v5.0.

Time frame: 21 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.